First-in-human Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influenza Vaccine fH1/DSP-0546LP

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This study is a single center, randomized, double-blind, placebo-controlled, dose-finding, FIH, Phase 1 study to assess the safety, tolerability, and immunogenicity of the adjuvanted Universal Influenza Vaccine (fH1/DSP-0546LP) after IM administrations in healthy adults.
Epistemonikos ID: 4aa755c15080f0be149ff2bee4d489edf068b8c5
First added on: Apr 17, 2026